EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.20
−0.56%Sep 3, 2026, 11:45 UTC
Emergent BioSolutions Inc. completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, spending about $68 million in cash at an average price of 90.6% of face value, reducing the outstanding balance to approximately $364.7 million.
Source:Sep 1, 2026, 11:55 UTC
Emergent BioSolutions received a contract modification valued at approximately $24 million from BARDA to supply CYFENDUS anthrax vaccine for preparedness efforts.
Source:Aug 31, 2026, 11:55 UTC
Emergent BioSolutions Inc. was awarded a standing offer by the Government of Canada to supply NARCAN Nasal Spray, effective from October 1, 2026, through September 30, 2029, with an option to extend for two additional years.
Source:Aug 10, 2026, 22:45 UTC
Levi & Korsinsky announced an investigation into potential securities law violations by Emergent BioSolutions regarding its prior guidance statements.
Source:Aug 5, 2026, 20:07 UTC
Emergent BioSolutions Inc. reported its financial results for the second quarter ended June 30, 2026.
Jun 29, 2026, 00:00 UTC
Emergent BioSolutions received a $52.7 million contract modification from the Office of the Assistant Secretary for Preparedness and Response to deliver ACAM2000 smallpox vaccine doses, ancillaries, and diluent replacement lots to the U.S. government by December 2026.
Source: